Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the ...

Total neoadjuvant therapy demonstrates consistent real-world efficacy across regimens in patients with locally advanced ...

EMA committee recommends approval of BeOne Medicines’ Tevimbra to treat neoadjuvant/adjuvant NSCLC: San Carlos, California Wednesday, July 30, 2025, 12:00 Hrs [IST] BeOne Medici ...

Atezolizumab enhances long-term outcomes in triple-negative breast cancer, revealing promising insights on ctDNA as a prognostic biomarker.

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

引言近年来，局部晚期直肠癌（LARC）治疗策略发展迅速，全程新辅助治疗（total neoadjuvant ...

ACCURATELY predicting which breast cancer patients will respond completely to neoadjuvant chemotherapy (NAC) remains a ...

CHICAGO — Neoadjuvant FOLFIRINOX chemotherapy failed to extend OS compared with upfront surgery for patients with resectable pancreatic head cancer, according to study results presented at ASCO ...

Background: Neoadjuvant therapy has emerged as a promising approach in the management of melanoma, offering potential advantages over traditional adjuvant therapy. Early immune activation and tumor ...

Dr. Stéphanie Gaillard and Dr. Bill Tew share updates to the evidence-based guideline on neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer. They highlight recommendations across ...